You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm said declines across most business areas were slightly offset by increases in sales of sample collection devices.
Revenue growth in Q2 was driven by strong sales of the company's Panorama noninvasive prenatal test and Horizon carrier screening test.
The viral assay, developed with Sentinel Diagnostics, improves the ability to monitor viral loads in critical organ transplant populations for the clinical management of infection.
The PCR diagnostic device is a palm-size, single-use, disposable device that detects N. gonorrhoeae and determines if it's susceptible to an antibiotic.
TargetCancer is activating two enrollment sites and setting up a remote consenting process so patients with rare cancers can be seen at local community hospitals.
The governors of the six states are collaborating with the Rockefeller Foundation to expand access to point-of-care antigen testing for SARS-CoV-2.
The firm will use the proceeds for working capital and other general corporate purposes, with the potential to acquire or invest in complementary businesses, technologies, or assets.
Koch Disruptive Technologies, Longliv Ventures, and OurCrowd participated in the round, bringing the firm's total funding to date to more than $124 million.
The PCR viral load test runs on the Cobas 6800/8800 systems and has been calibrated to the World Health Organization International Standard, Roche said.
The tests use a range of different specimens including self-collected nasal swabs, bronchoalveolar lavage, sputum, and nasopharyngeal washes.
The firm generated $46.2 million in revenues compared to $53.5 million in the prior year, which was better than analysts' estimate of $39.6 million.
The genetic testing company said its orders for traditional tests have also rebounded and are on track for growth in the second half of 2020.
GenMark has two SARS-CoV-2 tests that have received FDA Emergency Use Authorization, including a respiratory panel that tests for 21 pathogens.
The company posted Q2 revenues of $13.1 million, down from $13.5 million in Q2 2019 but above the consensus Wall Street estimate of $11.8 million.
The firm delivered record revenue and the most profitable quarter in its history as a result of the increased demand for its products.
On an adjusted basis at constant exchange rates, revenues grew 19 percent year over year, in line with guidance provided by the company in early July.
The company reported $41.8 million in total revenues for the quarter and said testing services revenues rose 41 percent year over year.
Coastal Genomics owns the Ranger gel electrophoresis technology to collect specific DNA target sizes, with applications in noninvasive prenatal testing and oncology.
According to Snibe, the test has 99.6 specificity and 100 percent sensitivity at 15 days following the onset of symptoms for COVID-19.
Of the 28 companies in the index, 22 firms saw their stock prices increase, while six firms' share prices decreased.
The firm said that its Diagnostics and Genomics segment sales were essentially flat, while its Protein Sciences segment sales were down 11 percent during Q4.
Antelope is currently developing a urine-based at-home test for the sexually transmitted infections Chlamydia trachomatis and Neisseria gonorrhoeae.
Oxford Immunotec said that a decrease in revenues for its US business was partly driven by the impact of planned inventory destocking by Quest Diagnostics.
Pathnova, will further develop and commercialize Todos' tests in Singapore, while Todos will assist Pathnova to commercialize its nasopharyngeal cancer tests.
Results from the Phase II INSPIRE study showed that change in ctDNA from baseline, as gauged by customized assays, predicted response to pembrolizumab.